Investigations of prion and virus safety of a new liquid IVIG product

Biologicals

Volumn 36, Issue 4, 2008, Pages 239-247

  Stucki, M ^a   Boschetti, N ^a   Schafer W ^b   Hostettler, T ^a   Kasermann F ^a,c   Nowak, T ^b   Groner A ^b   Kempf, C ^a,c  

^a ZLB Behring AG   (Switzerland)

^b CSL BEHRING GMBH   (Germany)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

IVIG; Pathogen safety; TSE; Virus

Indexed keywords

ALCOHOL; IMMUNOGLOBULIN; OCTANOIC ACID; PRION PROTEIN; PRIVIGEN; VIRUS DNA; VIRUS RNA;

ARTICLE; BIOASSAY; CHROMATOGRAPHY; DRUG MANUFACTURE; DRUG SAFETY; FILTRATION; HEPATITIS A VIRUS; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PARVOVIRUS; POLYMERASE CHAIN REACTION; PRION; PRIORITY JOURNAL; PSEUDORABIES HERPETOVIRUS; VIRUS; VIRUS DETECTION; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS; WESTERN BLOTTING;

ALGORITHMS; ANIMALS; BRAIN; BRAIN CHEMISTRY; CHEMICAL FRACTIONATION; CRICETINAE; DECONTAMINATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PRIONS; VIRUS INACTIVATION; VIRUSES;

EID: 45849137106     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2008.01.004     Document Type: Article

References (37)

1. Brown P., Brandel J.P., Preece M., and Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 67 (2006) 389-393
2. Boutoleau C., Guillon B., Martinez F., Vercelletto M., Faure A., and Feve J.R. Iatrogenic Creutzfeldt-Jakob disease subsequent to dural graft: persisting risk after 1987. Eur J Neurol 10 (2003) 521-523
3. Hewitt P.E., Llewelyn C.A., Mackenzie J., and Will R.G. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang 91 (2006) 348
4. Peden A.H., Head M.W., Ritchie D.L., Bell J.E., and Ironside J.W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 (2004) 527-529
5. Health Protection Agency. Fourth case of transfusion-associated variant-CJD infection. Health Protection Report (2007). http://www.hpa.org.uk/hpr/archives/2007/hpr0307.pdf 1/2007
6. Lee C.A., Ironside J.W., Bell J.E., Giangrande P., Ludlam C., Esiri M.M., et al. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 80 (1998) 909-911
7. Cervenakova L., Yakovleva O., McKenzie C., Kolchinsky S., McShane L., Drohan W.N., et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43 (2003) 1687-1694
8. Hunter N., Foster J., Chong A., McCutcheon S., Parnham D., Eaton S., et al. Transmission of prion diseases by blood transfusion. J Gen Virol 83 (2002) 2897-2905
9. Herzog C., Sales P.N., Etchegaray N., Charbonnier A., Freire S., Dormont D., et al. Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet 363 (2004) 422-428
10. Tateishi J., Kitamoto T., Mohri S., Satoh S., Sato T., Shepherd A., et al. Scrapie removal using Planova virus removal filters. Biologicals 29 (2002) 17-25
11. Truchot L., Arnaud T., Bloy C., and Perret-Liaudet A. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline). Biologicals 34 (2006) 227-231
12. Yunoki M., Urayama T., and Ikuta K. Possible removal of prion agents from blood products during the manufacturing process. Future Virol 1 (2006) 659-674
13. Kistler P., and Nitschmann H. Large scale production of human plasma fractions. Eight years experience with alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 7 (1962) 414-424
14. Cohn E.J., Strong L.E., Hughes Jr. W.L., Mulford D.J., Ashworth J.N., Melin M., et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 68 (1946) 459-475
15. Oncley J.L., Melin M., Richert D.A., Cameron J.W., and Gross Jr. P.M. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and â-lipoprotein into subfractions of human plasma. J Am Chem Soc 71 (1949) 541-550
16. Allary M., and Saint-Blancard J. Use of sodium caprylate for the separation of plasma proteins. Ann Pharm Fr 31 (1973) 513-520
17. Kempf C., Morgenthaler J.J., Rentsch M., and Omar A. Viral safety and manufacturing of an intravenous immunoglobulin. In: Kazatchkine M., and Morell A. (Eds). Intravenous immunoglobulin research and therapy (1996), The Parthenon Publishing Group, New York-London 11-18
18. Gregori L., Maring J.A., McAuley C., Dunston B., Kempf C., Rentsch M., et al. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32 (2004) 1-10
19. sc sensitive to proteinase K. J Gen Virol 84 (2003) 3173-3176
20. Vey M., Baron H., Weimer T., and Gröner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 30 (2002) 187-196
21. Safar J., Wille H., Itri V., Groth D., Serban H., Torchia M., et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med 4 (1998) 1157-1165
22. Cavalli-Sforza L. Biometrie: Grundzüge biologisch-medizinischer Statistik (1974), G Fischer, Stuttgart
23. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95 (1996), The European Agency for the Evaluation of Medicinal Products, London CPMP/BWP/268/95
24. Morel N., Simon S., Frobert Y., Volland H., Mourton-Gilles C., Negro A., et al. Selective and efficient immunoprecipitation of the disease-associated form of the prion protein can be mediated by nonspecific interactions between monoclonal antibodies and scrapie-associated fibrils. J Biol Chem 279 (2004) 30143-30149
25. Silveira J.R., Raymond G.J., Hughson A.G., Race R.E., Sim V.L., Hayes S.F., et al. The most infectious prion protein particles. Nature 437 (2005) 257-261
26. Cai K., Miller J.L., Stenland C.J., Gilligan K.J., Hartwell R.C., Terry J.C., et al. Solvent-dependent precipitation of prion protein. Biochim Biophys Acta 597 (2002) 28-35
27. Legname G., Baskakov I.V., Nguyen H.O., Riesner D., Cohen F.E., DeArmond S.J., et al. Synthetic mammalian prions. Science 305 (2004) 673-676
28. Safar J.G., Geschwind M.D., Deering C., Didorenko S., Sattavat M., Sanchez H., et al. Diagnosis of human prion disease. Proc Natl Acad Sci USA 102 (2005) 3501-3506
29. Bauman P.A., Lawrence L.A., Biesert L., Dichtelmüller H., Fabbrizzi F., Gajardo R., et al. Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang 91 (2006) 34-40
30. Boschetti N., Niederhauser I., Kempf C., Stühler A., Löwer J., and Blümel J. Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44 (2004) 1079-1086
31. Ros C., Baltzer C., Mani B., and Kempf C. Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology 345 (2006) 137-147
32. Mengeling W.L., and Paul P.S. Antibodies for autonomous parvoviruses of lower animals detected in human serum. Brief report. Arch Virol 88 (1986) 127-133
33. Habeeb A.F., and Francis R.D. Preparation of human immunoglobulin by caprylic acid precipitation. Prep Biochem 14 (1984) 1-17
34. Kempf C., Stucki M., and Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 35 (2007) 35-42
35. Korneyeva M., Hotta J., Lebing W., Rosenthal R.S., Franks L., and Petteway Jr. S.R. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 30 (2002) 153-162
36. Lundblad J.L., and Seng R.L. Inactivation of lipid-enveloped viruses in proteins by caprylate. Vox Sang 60 (1991) 75-81
37. Späth P., and Kempf C. Herstellung von intravenös verabreichbaren Immunglobulinen und Pathogensicherheit. In: Wahn V. (Ed). Klinischer Einsatz von intravenösen Immunglobulinen. 2nd ed. (2003), Bremen-London-Boston, UNI-MED Verlag AG 25-44